Results 11 to 20 of about 12,534 (220)

Decoding the Cardiac Immune Microenvironment and Fibroblast Crosstalk in Radiotherapy Combined with Immunotherapy‐Induced Cardiac Fibrosis Based on Single‐Cell Transcriptomic Analysis

Advanced Science
Purpose: The combination of radiotherapy and immunotherapy (radioimmunotherapy) shows promising antitumor efficacy but raises cardiotoxicity concerns. The underlying mechanisms remain unclear.
Yuxi Luo, Ying Yu, Zhimin Zeng, Yanxin Chen, Yali Yi, Zhiqin Lu, Fujuan Zeng, Peng Xu, Daya Luo, Leifeng Chen, Anwen Liu   +10 more
doaj   +2 more sources

Engineering MnPt Bimetallic Nanozymes for Cascade Enzymatic Therapy and Enhanced Radio‐Immunotherapy

Advanced Science
The immunosuppressive tumor microenvironment (TME) promotes resistance to radiation therapy, substantially limiting the efficacy of radioimmunotherapy. Here, we report a hyaluronic acid (HA)‐coated manganese–platinum (MnPt) bimetallic nanozyme (HD@MnO2 ...
Wenyi Zhang, Yangyang Guo, Guoping Xu, Luhaoxiang Liu, Lin Chen, Cai Zhang, Yiming Li, Jianmin Li, Yang Zhao   +8 more
doaj   +2 more sources

Pretargeted Radioimmunotherapy

International Journal of Radiation Oncology*Biology*Physics, 2006
This brief review covers the concept of pretargeted radioimmunotherapy and summarize the results obtained in preclinical animal models and initial phase I clinical trials. Reagents studied have been a bifunctional antibody prepared by crosslinking Fab' fragments from two antibodies with different specificity, one binding the target antigen expressed on
Ruby F, Meredith, Donald J, Buchsbaum
openaire   +4 more sources

Immunostimulatory effects of radioimmunotherapy [PDF]

Journal for ImmunoTherapy of Cancer, 2022
Radiation therapy (RT) is known for its ability to kill cancer cells in an immunogenic manner. Recent preclinical data demonstrate that targeted alpha-particle therapy shares with RT the capacity to elicit immunostimulatory effects, standing out as a promising strategy to circumvent immune checkpoint inhibitor resistance in immunologically ‘cold ...
Constanzo, Julie, Galluzzi, Lorenzo, Pouget, Jean-Pierre   +2 more
openaire   +3 more sources

Differentiated T Lymphocytes and Cancer Cell Mitochondrial Metabolism to Enhance Radioimmunotherapy by a Biomimetic Nanozyme System. [PDF]

Adv Sci (Weinh)
T cell membrane‐coated MgCO3/Fe‐CD nanozyme loaded with TEPP‐46 (TFMP) enhances breast cancer radioimmunotherapy by reprogramming mitochondrial metabolism in T cells and tumors. It targets PD‐L1, converts H2O2 into ROS, neutralizes acidity, and releases Mg2⁺/TEPP‐46 to boost T cell activation.
Zhang H, Deng Y, Lu Y, Wang M, Qiao K, Yang Z, Ning S, Liu T.   +7 more
europepmc   +2 more sources

Immunotherapy and Radioimmunotherapy for Desmoplastic Small Round Cell Tumor

Frontiers in Oncology, 2021
Desmoplastic small round cell tumor (DRSCT) is a highly aggressive primitive sarcoma that primarily affects adolescent and young adult males. The 5-year survival rate is 15-30% and few curative treatment options exist.
Madelyn Espinosa-Cotton, Nai-Kong V. Cheung   +1 more
doaj   +1 more source

Clinical radioimmunotherapy

Seminars in Radiation Oncology, 2000
Radioimmunotherapy (RIT) is a promising new therapy for the treatment of a variety of malignancies. General principles of RIT are discussed, including important considerations in the selection of monoclonal antibodies (MAb) and radionuclides for RIT.
S J, Knox, R F, Meredith
openaire   +2 more sources

Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 in men with metastatic castration-resistant prostate cancer

Frontiers in Oncology, 2013
Radioimmunotherapy has demonstrated efficacy with acceptable toxicity leading to approval in non-Hodgkin’s lymphoma, but has been slower to develop for the treatment of advanced solid tumors.
Scott T Tagawa, Scott T Tagawa, Naveed Hassan Akhtar, Anastasia eNikolopoulou, Gurveen eKaur, Brian eRobinson, Renee eKahn, Shankar eVallabhajosula, Stanley J Goldsmith, David M Nanus, David M Nanus, Neil H Bander   +11 more
doaj   +1 more source

Fate of 177Lu-CHX-A”-DTPA-Rituximab: In vitro Evaluation in Raji Cell Line

Journal of Radiation and Cancer Research, 2023
Context: Radioimmunotherapy is an emerging treatment modality for various types of cancers. While immunotherapy using monoclonal antibodies has shown promising results, particularly in hematological malignancies, a significant number of patients develop ...
Saloni Arun Samant, Chandan Kumar, Usha Pandey   +2 more
doaj   +1 more source

Preclinical efficacy of hK2 targeted [177Lu]hu11B6 for prostate cancer theranostics [PDF]

, 2019
Androgen ablating drugs increase life expectancy in men with metastatic prostate cancer, but resistance inevitably develops. In a majority of these recurrent tumors, the androgen axis is reactivated in the form of increased androgen receptor (AR ...
Beattie, Bradley J., Beattie, Kai A., Elgqvist, Jörgen, Eriksson, Sophie E., Larsson, Erik, Strand, Sven-Erik, Thorek, Daniel L. J., Timmermand, Oskar Vilhelmsson, Tran, Thuy A., Ulmert, David, Örbom, Anders   +10 more
core   +2 more sources